Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Ventyx Biosciences
What AI says about Ventyx Biosciences
Ventyx Biosciences specializes in creating small molecule therapeutics for conditions with high unmet medical needs. Their lead portfolio includes NLRP3 inhibitors and therapies for inflammatory bowel disease, all currently in clinical development.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
NLRP3 Inhibitors
A portfolio of inhibitors targeting the NLRP3 pathway, including VTX2735 and VTX3232, aimed at treating recurrent pericarditis and neurodegenerative diseases.
Inflammatory Bowel Disease Therapies
Includes tamuzimod and VTX958, which are designed to modulate pathways involved in inflammatory bowel diseases and have completed Phase 2 clinical trials.
Common Questions
What types of diseases does Ventyx Biosciences focus on?
Ventyx Biosciences focuses on autoimmune, inflammatory, and neurodegenerative diseases.
What is the current stage of Ventyx's drug development?
Ventyx is a clinical-stage biopharmaceutical company with several products in Phase 2 clinical trials.
What are NLRP3 inhibitors?
NLRP3 inhibitors are small molecule therapeutics developed by Ventyx to target the NLRP3 pathway, which is involved in various inflammatory conditions.